Effects of bone sialoprotein on pancreatic cancer cell growth, invasion and metastasis

Cancer Letters

Volumn 245, Issue 1-2, 2007, Pages 171-183

  Kayed, Hany ^a   Kleeff, Jörg ^a   Keleg, Shereen ^a   Felix, Klaus ^a   Giese, Thomas ^a   Berger, Martin R ^b   Büchler, Markus W ^a   Friess, Helmut ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Glycoprotein; Invasion; Metastasis; Proliferation

Indexed keywords

BONE SIALOPROTEIN; COMPLEMENTARY DNA; MESSENGER RNA; RECOMBINANT PROTEIN;

ARTICLE; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC PANCREATITIS; CONTROLLED STUDY; DNA MICROARRAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA;

CARCINOMA, PANCREATIC DUCTAL; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTEGRIN-BINDING SIALOPROTEIN; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; RADIOIMMUNOASSAY; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIALOGLYCOPROTEINS;

EID: 33845606215     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.01.002     Document Type: Article

References (56)

1. Fisher L.W., Whitson S.W., Avioli L.V., and Termine J.D. Matrix sialoprotein of developing bone. J. Biol. Chem. 258 (1983) 12723-12727
2. Kim R.H., Shapiro H.S., Li J.J., Wrana J.L., and Sodek J. Characterization of the human bone sialoprotein (BSP) gene and its promoter sequence. Matrix Biol. 14 (1994) 31-40
3. Wuttke M., Muller S., Nitsche D.P., Paulsson M., Hanisch F.G., and Maurer P. Structural characterization of human recombinant and bone-derived bone sialoprotein. Functional implications for cell attachment and hydroxyapatite binding. J. Biol. Chem. 276 (2001) 36839-36848
4. Bellahcene A., Kroll M., Liebens F., and Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J. Bone Miner. Res. 11 (1996) 665-670
5. Bellahcene A., Merville M.P., and Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res. 54 (1994) 2823-2826
6. Bautista D.S., Xuan J.W., Hota C., Chambers A.F., and Harris J.F. Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J. Biol. Chem. 269 (1994) 23280-23285
7. Chellaiah M., Fitzgerald C., Filardo E.J., Cheresh D.A., and Hruska K.A. Osteopontin activation of c-src in human melanoma cells requires the cytoplasmic domain of the integrin alpha v-subunit. Endocrinology 137 (1996) 2432-2440
8. Xuan J.W., Hota C., Shigeyama Y., D'Errico J.A., Somerman M.J., and Chambers A.F. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J. Cell Biochem. 57 (1995) 680-690
9. Van der Pluijm G., Vloedgraven H.J., Ivanov B., Robey F.A., Grzesik W.J., Robey P.G., et al. Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res. 56 (1996) 1948-1955
10. Adwan H., Bauerle T., Najajreh Y., Elazer V., Golomb G., and Berger M.R. Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int. J. Oncol. 24 (2004) 1235-1244
11. Chen J., De S., Brainard J., and Byzova T.V. Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Commun. Adhes. 11 (2004) 1-11
12. Matsuno S., Kobari M., Matsuda Y., and Sato T. Diagnosis of carcinoma of the pancreas by assay of immunosuppressive acidic protein. Tohoku J. Exp. Med. 136 (1982) 1-10
13. Takahashi H., Miyazaki H., Deura M., Shimizu Y., Asukata I., and Kameda H. Clinical evaluation of CA 19-9, TPA, IAP and 5′-NPD-V as tumor markers of hepatocellular, bile duct and pancreas carcinoma. Gan. No. Rinsho. 31 (1985) 623-630
14. Koopmann J., Fedarko N.S., Jain A., Maitra A., Iacobuzio-Donahue C., Rahman A., et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 13 (2004) 487-491
15. Kolb A., Kleeff J., Guweidhi A., Esposito I., Giese N.A., Adwan H., et al. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol. Ther. 4 (2005)
16. Sedivy R., Kalipciyan M., Mazal P.R., Wolf B., Wrba F., Karner-Hanusch J., et al. Osteoclast-like giant cell tumor in mucinous cystadenocarcinoma of the pancreas: an immunohistochemical and molecular analysis. Cancer Detect. Prev. 29 (2005) 8-14
17. Sedivy R., Peters K., and Kloppel G. Osteopontin expression in ductal adenocarcinomas and undifferentiated carcinomas of the pancreas. Virchows Arch. 446 (2005) 41-45
18. Nakamura M., Oka M., Iizuka N., Kawauchi S., Gondo T., Ueno T., and Tangoku A. Osteopontin expression in chronic pancreatitis. Pancreas 25 (2002) 182-187
19. O'Brien K.D., Kuusisto J., Reichenbach D.D., Ferguson M., Giachelli C., Alpers C.E., and Otto C.M. Osteopontin is expressed in human aortic valvular lesions. Circulation 92 (1995) 2163-2168
20. Nitta K., Ishizuka T., Horita S., Hayashi T., Ajiro A., Uchida K., et al. Soluble osteopontin and vascular calcification in hemodialysis patients. Nephron 89 (2001) 455-458
21. Canfield A.E., Farrington C., Dziobon M.D., Boot-Handford R.P., Heagerty A.M., Kumar S.N., and Roberts I.S. The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study. J. Pathol. 196 (2002) 228-234
22. Moe S.M., O'Neill K.D., Duan D., Ahmed S., Chen N.X., Leapman S.B., et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 61 (2002) 638-647
23. Chen N.X., O'Neill K.D., Duan D., and Moe S.M. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cell. Kidney Int. 62 (2002) 1724-1731
24. Makiishi-Shimobayashi C., Tsujimura T., Iwasaki T., Kakihana M., Shimano K., Terada N., and Sakagami M. Localization of osteopontin at calcification sites of cholesteatoma: possible role as a regulator of deposition of calcium phosphate in the middle ear. Auris Nasus Larynx 31 (2004) 3-9
25. Makiishi-Shimobayashi C., Tsujimura T., Sugihara A., Iwasaki T., Yamada N., Terada N., and Sakagami M. Expression of osteopontin by exudate macrophages in inflammatory tissues of the middle ear: a possible association with development of tympanosclerosis. Hear. Res. 153 (2001) 100-107
26. Bachem M.G., Schneider E., Gross H., Weidenbach H., Schmid R.M., Menke A., et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 115 (1998) 421-432
27. Guo J., Kleeff J., Li J., Ding J., Hammer J., Zhao Y., et al. Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene 23 (2004) 71-81
28. Kayed H., Kleeff J., Keleg S., Guo J., Ketterer K., Berberat P.O., et al. Indian hedgehog signaling pathway: expression and regulation in pancreatic cancer. Int. J. Cancer 110 (2004) 668-676
29. Ketterer K., Rao S., Friess H., Weiss J., Buchler M.W., and Korc M. Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer. Clin. Cancer Res. 9 (2003) 5127-5136
30. Garcia J.M., Martins M.D., Jaeger R.G., and Marques M.M. Immunolocalization of bone extracellular matrix proteins (type I collagen, osteonectin and bone sialoprotein) in human dental pulp and cultured pulp cells. Int. Endod. J. 36 (2003) 404-410
31. Zou H., Osborn N.K., Harrington J.J., Klatt K.K., Molina J.R., Burgart L.J., and Ahlquist D.A. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 830-834
32. Cheung H.W., Ching Y.P., Nicholls J.M., Ling M.T., Wong Y.C., Hui N., et al. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. Mol. Carcinog. 43 (2005) 237-245
33. Nakano T., Tani M., Nishioka M., Kohno T., Otsuka A., Ohwada S., and Yokota J. Genetic and epigenetic alterations of the candidate tumor-suppressor gene MYO18B, on chromosome arm 22q, in colorectal cancer. Genes Chromosomes Cancer 43 (2005) 162-171
34. Enokida H., Shiina H., Urakami S., Igawa M., Ogishima T., Pookot D., et al. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, caucasian and Asian patients with prostate cancer. Int. J. Cancer 116 (2005) 174-181
35. Okami J., Simeone D.M., and Logsdon C.D. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res. 64 (2004) 5338-5346
36. Miller A.D., Van Hoeven N.S., and Liu S.L. Transformation and scattering activities of the receptor tyrosine kinase RON/Stk in rodent fibroblasts and lack of regulation by the jaagsiekte sheep retrovirus receptor, Hyal2. BMC Cancer 4 (2004) 64
37. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J. Clin. 55 (2005) 10-30
38. Bellahcene A., Albert V., Pollina L., Basolo F., Fisher L.W., and Castronovo V. Ectopic expression of bone sialoprotein in human thyroid cancer. Thyroid 8 (1998) 637-641
39. Bellahcene A., Antoine N., Clausse N., Tagliabue E., Fisher L.W., Kerr J.M., et al. Detection of bone sialoprotein in human breast cancer tissue and cell lines at both protein and messenger ribonucleic acid levels. Lab. Invest. 75 (1996) 203-210
40. Bellahcene A., Maloujahmoum N., Fisher L.W., Pastorino H., Tagliabue E., Menard S., and Castronovo V. Expression of bone sialoprotein in human lung cancer. Calcif. Tissue Int. 61 (1997) 183-188
41. Waltregny D., Bellahcene A., Van Riet I., Fisher L.W., Young M., Fernandez P., et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J. Natl Cancer Inst. 90 (1998) 1000-1008
42. Bellahcene A., and Castronovo V. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases. Bull. Cancer 84 (1997) 17-24
43. Bellahcene A., Menard S., Bufalino R., Moreau L., and Castronovo V. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int. J. Cancer 69 (1996) 350-353
44. Smit J.W., Van der Pluijm G., Vloedgraven H.J., Lowik C.W., and Goslings B.M. Role of integrins in the attachment of metastatic follicular thyroid carcinoma cell lines to bone. Thyroid 8 (1998) 29-36
45. Carlinfante G., Vassiliou D., Svensson O., Wendel M., Heinegard D., and Andersson G. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin. Exp. Metastasis 20 (2003) 437-444
46. Jung K., Lein M., Stephan C., Von Hosslin K., Semjonow A., Sinha P., et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int. J. Cancer 111 (2004) 783-791
47. Hughes D.E., Salter D.M., Dedhar S., and Simpson R. Integrin expression in human bone. J. Bone Miner. Res. 8 (1993) 527-533
48. Duongand L.T., and Rodan G.A. Integrin-mediated signaling in the regulation of osteoclast adhesion and activation. Front. Biosci. 3 (1998) d757-d768
49. Ross F.P., Chappel J., Alvarez J.I., Sander D., Butler W.T., Farach-Carson M.C., et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J. Biol. Chem. 268 (1993) 9901-9907
50. Waltregny D., Bellahcene A., de Leval X., Florkin B., Weidle U., and Castronovo V. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J. Bone Miner. Res. 15 (2000) 834-843
51. Chen J., Rodriguez J.A., Barnett B., Hashimoto N., Tang J., and Yoneda T. Bone sialoprotein promotes tumor cell migration in both in vitro and in vivo models. Connect. Tissue Res. 44 Suppl. 1 (2003) 279-284
52. Sharp J.A., Waltham M., Williams E.D., Henderson M.A., and Thompson E.W. Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin. Exp. Metastasis 21 (2004) 19-29
53. Keeleyand F.W., and Sitarz E.E. Identification and quantitation of alpha 2-HS-glycoprotein in the mineralized matrix of calcified plaques of atherosclerotic human aorta. Atherosclerosis 55 (1985) 63-69
54. Peerschke E.I., Minta J.O., Zhou S.Z., Bini A., Gotlieb A., Colman R.W., and Ghebrehiwet B. Expression of gC1q-R/p33 and its major ligands in human atherosclerotic lesions. Mol. Immunol. 41 (2004) 759-766
55. McKee M.D., Nanci A., and Khan S.R. Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J. Bone Miner. Res. 10 (1995) 1913-1929
56. Wang A., Martin J.A., Lembke L.A., and Midura R.J. Reversible suppression of in vitro biomineralization by activation of protein kinase A. J. Biol. Chem. 275 (2000) 11082-11091